Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2012 - 2026)

Enanta Pharmaceuticals' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$716000.0 for Q1 2026.

• Quarterly Change in Accured Expenses rose 63.71% year-over-year to -$716000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$951000.0 (up 66.28% YoY) and the FY2025 annual result came in at $58000.0, up 101.03% from the prior year.
• Change in Accured Expenses was -$716000.0 for Q1 2026 at Enanta Pharmaceuticals, up from -$5.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.7 million in Q2 2023 and bottomed at -$6.7 million in Q4 2023.
• A 5-year average of -$1.2 million and a median of -$716000.0 in 2026 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses sank 277.88% — and 2025, when it surged 502.99%.
• Enanta Pharmaceuticals' Change in Accured Expenses stood at -$6.6 million in 2022, then fell by 2.08% to -$6.7 million in 2023, then surged by 56.8% to -$2.9 million in 2024, then slumped by 77.87% to -$5.2 million in 2025, then jumped by 86.17% to -$716000.0 in 2026.
• Business Quant data shows ENTA's Change in Accured Expenses at -$716000.0 in Q1 2026, -$5.2 million in Q4 2025, and $2.4 million in Q3 2025.